Daewon Pharm (003220) — Capital Reinvestment Ratio
Daewon Pharm (003220) has a Capital Reinvestment Ratio of 0.43x as of December 2025, meaning it reinvests 0% of its operating cash flow (₩30.61 Billion) in capital expenditures (₩13.07 Billion). See 003220 net asset quality score to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Daewon Pharm Capital Reinvestment Ratio (2011–2025)
This chart tracks Daewon Pharm's Capital Reinvestment Ratio across 15 annual periods. Check how aggressively does Daewon Pharm reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Daewon Pharm (2011–2025)
Year-by-year Capital Reinvestment Ratio for Daewon Pharm from 2011 to 2025. For live market cap and broader valuation context, see market cap of Daewon Pharm.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.00x | ₩42.31 Billion | ₩42.13 Billion | ▼ -44.2% |
| 2024 | 1.78x | ₩30.04 Billion | ₩53.58 Billion | ▲ +347.8% |
| 2023 | 0.40x | ₩51.73 Billion | ₩20.61 Billion | ▼ -0.7% |
| 2022 | 0.40x | ₩33.33 Billion | ₩13.37 Billion | ▲ +119.0% |
| 2021 | 0.18x | ₩22.41 Billion | ₩4.10 Billion | ▼ -59.7% |
| 2020 | 0.45x | ₩24.95 Billion | ₩11.35 Billion | ▼ -57.4% |
| 2019 | 1.07x | ₩30.97 Billion | ₩33.03 Billion | ▲ +4.6% |
| 2018 | 1.02x | ₩40.03 Billion | ₩40.82 Billion | ▼ -70.4% |
| 2017 | 3.45x | ₩4.27 Billion | ₩14.71 Billion | ▲ +248.6% |
| 2016 | 0.99x | ₩20.79 Billion | ₩20.57 Billion | ▲ +29.0% |
| 2015 | 0.77x | ₩25.82 Billion | ₩19.80 Billion | ▼ -15.5% |
| 2014 | 0.91x | ₩17.45 Billion | ₩15.84 Billion | ▲ +13.6% |
| 2013 | 0.80x | ₩12.32 Billion | ₩9.85 Billion | ▲ +234.6% |
| 2012 | 0.24x | ₩13.83 Billion | ₩3.30 Billion | ▼ -58.0% |
| 2011 | 0.57x | ₩17.93 Billion | ₩10.19 Billion | — |